We
assessed the safety/efficacy profile of prophylactic doses of
low-molecular- weight heparin (LMWH).... ///Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation... ///It is still debated whether prophylactic doses of low-molecular- weight heparin (LMWH) are always effective in preventing Venous Thromboembolism (VTE) and mortality in COVID-19....
The main drug for the prevention of "cytokine storm" is low-molecular weight heparin
enoxaparin sodium (Enixum®) in therapeutic doses. We use this drug for all patients who have
SpO2 ≤ 93% (with COPD SpO2 ≤ 84%) without oxygen subsidies.... ///Effective treatment regimen Famotidine with low molecular weight heparin (sodium enoxaparin) severe stages patients COVID-19...
.:(0123456789)1 3
Journal of Thrombosis and Thrombolysis
https://doi.org/10.1007/s11239-021-02460-0
CORRECTION
Correction to: Use of low‑molecular weight heparin, transfusion
and mortality in COVID‑19 patients not requiring ventilation
Elvira Grandone1,2... ///Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation (Journal of Thrombosis and Thrombolysis, (2021), 10.1007/s11239-021-02429-z)...
weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era Thrombosis ResearchJournalmolecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era...
BCG, muramylpeptides, trained immunity (part II): a low molecular weight
alternative to multicomponent bacterial immunostimulants for prevention of respiratory infections during a pandemic. Terapevticheskii
Arkhiv (Ter.... ///BCG, muramylpeptides, trained immunity (part II): A low molecular weight alternative to multicomponent bacterial immunostimulants for prevention of respiratory infections during a pandemic... The review analyzes the linkages between BCG, mycobacterial adjuvants, bacterial lysates, trained immunity, muramylpeptides (MPs) and NOD2 receptors in light of the choice of a low molecular weight alternative to multicomponent bacterial immunostimulants...
Role of heparins in the therapy of severe conditions in patients with COVID-19... At this stage of understanding the pathophysiology of coronavirus infection, it is worth considering the use of low-molecular-weight heparins in patients with severe COVID-19, including those with sepsis-induced coagulopathy....
///Hemostasis system in covid-19 patients with heparin therapy... All patients received low molecular weight heparins at therapeutic dosages relatively to body weight in accordance with the hospital proto-col for patients with COVID-19. Results....
molecular weight heparins (LMWH) which are also recommended for an outpatient COVID-19 patient The prescription of low molecular weight heparin, the duration of their use and doses should be decided on the basis of a risk assessment of factors for each...
CIC may be complicated by sepsis,
antiphospholipid syndrome, hemophagocytic syndrome, thrombotic microangiopathy, and heparin-induced thrombocytopenia.
The main therapy is low molecular weight heparins treatment.... CIC may be complicated by sepsis, antiphospholipid syndrome, hemophagocytic syndrome, thrombotic microangiopathy, and heparin-induced thrombocytopenia. The main therapy is low molecular weight heparins treatment....
